20 April 2021 – Race Oncology Limited (“Race”) is pleased to announce the appointment of Dr David Fuller as Chief Medical Officer (CMO). This appointment follows the announcement by Race on 19 February 2021 that the Company would be recruiting a full-time, Australian- based CMO to drive its three-pillar strategy forward.
An internationally experienced biopharmaceutical executive and physician, Dr Fuller brings a deep understanding of the successful development & commercialisation of novel pharmaceuticals. His 30 years of R&D experience spans large, mid and small cap companies including pre-clinical and clinical development, medical and regulatory affairs, and commercialisation.
Dr Fuller will join Race Oncology on 1 July 2021 from Syneos Health Clinical Solutions, where he has been the Senior Vice President of Clinical Development in the Oncology Business Unit. Dr Fuller also currently serves as Chairman for EpiAxis Therapeutics, a privately owned epigenetic therapeutic and diagnostic company, and is a Non-Executive Director of the ASX- listed biotech company, AdAlta (ASX: 1AD).
Dr Fuller was formerly a Director at Linear Clinical Research, Chairman of Dimerix Bioscience, CMO/COO at Trident Clinical Research, CMO at Arana Therapeutics, and Vice-President Clinical at Genzyme Europe.
During his career, he has directly led successful major market drug approvals including Moraxen (UK), Busulfex (US Paediatrics and EU Adult indications), Xyrem (US) and Renagel (EU). He has also designed and executed multiple Phase I, II and III studies (US, EU, Asia) for both orphan and non-orphan drug products.
This is an important appointment for Race as David brings significant experience and capability. David has been successful in developing a number of pharmaceutical products across various international markets and we look forward to his future guidance in optimising plans for the execution of our Three Pillar strategy and maximising the significant opportunities we have ahead for Bisantrene.Race Oncology CEO and Managing Director, Phil Lynch
I am honoured and excited to be joining Race at such a critical time in the Company’s evolution given the huge potential of Bisantrene as both a targeted precision oncology drug and a differentiated chemotherapeutic. I look forward to applying my experience and expertise to help Race successfully realise the objectives of its three-pillar strategy. And I am pleased to have a new opportunity to again work with Professor Borje Anderson after our successful prior collaboration on Busulfex.Dr David Fuller
Dr Fuller holds a Bachelor of Medicine / Bachelor of Surgery degree, and a Bachelor of Pharmacy (First Class Honours in Pharmacology), both from University of Sydney. He is also a Member of the American Society Clinical Oncology (ASCO).